logo
Plus   Neg
Share
Email
Comment

Boston Scientific Q4 Preliminary Sales Up 9.9%

Boston Scientific Corp. (BSX) reported preliminary sales for the fourth quarter ended December 31, 2017 was about $2.41 billion, which represented growth of approximately 9.9 percent on a reported basis, approximately 8.1 percent on an operational basis and approximately 6.8 percent on an organic basis. Analysts polled by Thomson Reuters expect the company to report revenues of $2.35 billion for the fourth-quarter. Analysts' estimates typically exclude special items.

Organic revenue growth excludes the impact of changes in foreign currency exchange rates and sales from the acquisitions of EndoChoice Holdings, Inc. and Symetis SA, with no prior year comparable sales.

For the year ended December 31, 2017, the company generated sales of approximately $9.05 billion. This represented growth of approximately 7.9 percent on a reported basis, approximately 7.8 percent on an operational basis and about 6.6 percent on an organic basis, all compared to the prior year period. Analysts expect annual revenue of $8.99 billion.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Amid a government shutdown, the Senate voted Monday to move forward on a short-term spending bill to re-open the government. The Senate voted 81 to 18 in favor of limiting debate on the bill, which would fund the government through February 8th. Opera, a web browser for Windows, macOS, and Linux operating systems, has added cryptocurrency mining protection to its mobile browsers. It is part of the browser's ad blocker function. In its desktop-based versions, Opera had introduced cryptocurrency miner protection in early January. French drug giant Sanofi SA Monday announced an agreement to buy US-based hemophilia drugmaker Bioverativ Inc. (BIVV) for around $11.6 billion. The deal expands Sanofi's presence in specialty care and strengthens leadership in rare diseases. Sanofi shares were losing around 4 percent in the early morning trading in Paris.
comments powered by Disqus
Follow RTT